Cas No.Product NameDescription
936091-26-8TG101348TG-101348 is a potent, highly selective JAK2 inhibitor.
941678-49-5RuxolitinibRuxolitinib is an orally bioavailable, potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively.
936091-14-4TG101209TG101209 is a potent and small molecule JAK2-selective kinase inhibitor with IC50 of 6, 25, 17 and 169 nM for JAK2, FLT3, RET and JAK3, respectively.
477600-75-2TofacitinibTasocitinib also known as CP690550 is an JAK kinase inhibitor.
1187594-09-7BaricitinibBaricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).
134678-17-4LamivudineLamivudine is a potent nucleoside analog reverse transcriptase inhibitor with an IC50 of 2.7 mM.
195371-52-9JAK2 Inhibitor V Z3 Z3 is a novel specific inhibitor of Jak2 tyrosine kinase. Z3 inhibited Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.
111358-88-4LestaurtinibPotent JAK2, FLT3 and TrkA inhibitor (IC50 values are 0.9, 3 and < 25 nM respectively) that prevents STAT5 phosphorylation (IC50 = 20 - 30 nM).
4452-06-6ZM 449829JAK3 Inhibitor V is a potent, selective inhibitor of JAK3 (Janus tyrosine kinase 3) which binds competitively to the JAK3 ATP site.
1271022-90-2BMS-911543BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1?nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively.
540737-29-9Tofacitinib citrate Tasocitinib also known as CP690550 is an JAK kinase inhibitor.
1206101-20-3GLPG0634 analogGLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases.
945755-56-6XL019 XL019 is a potent and selective JAK2 inhibitor.
1206161-97-8GLPG0634GPLG0634 is a novel inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively in vitro.
937272-79-2Pacritinib Pacritinib, is an orally bioavailable inhibitor of Janus kinase 2 and the JAK2 mutant JAK2V617F with potential antineoplastic activity.
211555-04-3WHI-P154WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
944842-54-0DecernotinibDecernotinib(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.
1334298-90-6INCB39110Itacitinib (INCB039110) is an oral selective JAK1 inhibitor.
941685-37-6Ruxolitinib S enantiomerS enantiomer of Ruxolitinib; Ruxolitinib(INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
1187595-84-1Baricitinib phosphateBaricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway